Sara Moniuszko is a health and lifestyle reporter at CBSNews.com. Previously, she wrote for USA Today, where she was selected to help launch the newspaper's wellness vertical. She now covers breaking ...

When someone has whooping cough, the sound can be unmistakable: A deep, gasping "whoop" as they struggle to catch their breath between fits of coughing. Now, this once-rare illness, also known as ...

Fevers, fatigue, and a changing complexion? Why modern doctors are still trying to make sense of the symptoms the celebrated novelist experienced before her death at age 41. This portrait of Jane ...

In 2023, letters written by Jacqueline Kennedy-Onassis went up for auction. Penned in the summer of 1958 during John F. Kennedy's time in the Senate, the letters were addressed to Kennedy-Onassis's ...

Merck & Co., Inc. (NYSE:MRK) is one of the Most Undervalued Growth Stocks to Buy According to Hedge Funds. On September 19, Merck & Co., Inc. (NYSE:MRK) announced that its ENFLONSIA has received a ...

The Centre of Excellence in Clinical Genetics at B J Medical College (BJMC) and Sassoon General Hospital (SGH) has screened over 150 newborns for genetic disorders since its launch in October last ...

In this article, we will look at the 11 Most Undervalued Growth Stocks to Buy According to Hedge Funds. On September 25, Stephen Parker, JPMorgan Private Bank’s co-head of global investment strategy, ...

LONDON - Vikings receiver Jordan Addison didn’t play in the first quarter Sunday vs. Cleveland because he missed a walkthrough practice last week. He didn’t catch a pass until the third quarter.

Jordan Addison was the hero of Sunday morning's game between the Minnesota Vikings and Cleveland Browns in London, catching the game-winning touchdown with 25 seconds left in the fourth quarter, but ...

Vikings receiver Jordan Addison had a big play in the fourth quarter of last Sunday’s game in Ireland. In the first quarter of Sunday’s game in London, Addison didn’t play at all. Via Ian Rapoport of ...

Several major advances in Crohn's disease have marked 2025, including two new FDA-approved therapies, emerging biologics that target novel pathways, and the first global standards for managing ...